Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD+ immune cells

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2847-2858

  Yang, Sidi ^a   Chen, Yufei ^a   Kaien, Gu ^a   Dash, Alicia ^a   Sayre, Casey L ^a   Davies, Neal M ^a   Ho, Emmanuel A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antibody conjugation; HIV AIDS; Intravaginal gel; Microbicide; Nanoparticles; Saquinavir

Indexed keywords

CD4 ANTIBODY; CD4 ANTIGEN; HYDROXYETHYLCELLULOSE; NANOPARTICLE; PLACEBO; POLYGLACTIN; SAQUINAVIR;

ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG RETENTION; DRUG SELF ADMINISTRATION; DRUG TARGETING; ENCAPSULATION; EPITHELIUM CELL; GEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INTRAVAGINAL DRUG ADMINISTRATION; NANOMEDICINE; POST EXPOSURE PROPHYLAXIS; VAGINA; VAGINA EPITHELIUM;

ANTIBODY CONJUGATION; HIV/AIDS; INTRAVAGINAL GEL; MICROBICIDE; NANOPARTICLES; SAQUINAVIR;

ANTIBODIES; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL SURVIVAL; CELLULOSE; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; NANOCAPSULES; SAQUINAVIR; VAGINAL CREAMS, FOAMS, AND JELLIES; VISCOSITY;

EID: 84881294235     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S46958     Document Type: Article

References (69)

1. Parker R. The global HIV/AIDS pandemic, structural inequalities, and the politics of international health. Am J Public Health. 2002;92(3): 343-346.
2. Joint United Nations Programme on HIV/AIDS. UNAIDS 2011 World AIDS Day Report - 2011. Geneva: UNAIDS; 2011.
3. World Health Organization. Women and Health: Today's Evidence - Tomorrow's Agenda. Geneva: WHO; 2009.
4. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep. 2009;6(1):20-28.
5. Smith SM. Pre-exposure chemoprophylaxis for HIV: it is time. Retrovirology. 2004;1:16.
6. Youle M, Wainberg MA. Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. J Int Assoc Physicians AIDS Care (Chic). 2003;2(3):102-105.
7. Garg AB, Nuttall J, Romano J. The future of HIV microbicides: challenges and opportunities. Antivir Chem Chemother. 2009;19(4):143-150.
8. Vella S, Floridia M. Saquinavir. Clinical pharmacology and efficacy. Clin Pharmacokinet. 1998;34(3):189-201.
9. Miller CJ, Shattock RJ. Target cells in vaginal HIV transmission. Microbes Infect. 2003;5(1):59-67.
10. Hladik F, Sakchalathorn P, Ballweber L, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 2007;26(2):257-270.
11. Joag SV, Adany I, Li ZA, et al. Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS. J Virol. 1997;71(5):4016-4023.
12. Govender T, Ojewole E, Naidoo P, Mackraj I. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv. 2008;15(8): 493-501.
13. Mallipeddi R, Rohan LC. Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomedicine. 2010;5:533-547.
14. Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, Gendelman HE. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-Infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol. 2010;5(4):592-601.
15. Peer D. Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review. J Control Release. 2010;148(1):63-68.
16. McNeil SE. Nanotechnology for the biologist. J Leukoc Biol. 2005; 78(3):585-594.
17. Gandapu U, Chaitanya RK, Kishore G, Reddy RC, Kondapi AK. Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. Plos One. 2011;6(8):e23388.
18. Dou H, Destache CJ, Morehead JR, et al. Development of a macrophagebased nanoparticle platform for antiretroviral drug delivery. Blood. 2006;108(8):2827-2835.
19. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release. 2006;112(1):26-34.
20. Arruebo M, Valladares M, Gonzalez-Fernandez A. Antibodyconjugated nanoparticles for biomedical applications. J Nanomaterials. 2009;2009:439389.
21. Date AA, Shibata A, Goede M, et al. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Res. 2012;96(3):430-436.
22. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21(23):2475-2490.
23. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3): 1377-1397.
24. Crotts G, Park TG. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. J Microencapsul. 1998;15(6):699-713.
25. Kranz H, Ubrich N, Maincent P, Bodmeier R. Physicomechanical properties of biodegradable poly(D,L-lactide) and poly(D,L-lactide-coglycolide) films in the dry and wet states. J Pharm Sci. 2000;89(12): 1558-1566.
26. Campolongo MJ, Luo D. Drug delivery: old polymer learns new tracts. Nat Mater. 2009;8(6):447-448.
27. Bicho A, Peca IN, Roque ACA, Cardoso MM. Anti-CD8 conjugated nanoparticles to target mammalian cells expressing CD8. Int J Pharm. 2010;399(1-2):80-86.
28. Farokhzad OC, Cheng JJ, Teply BA, et al. Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103(16):6315-6320.
29. Geldenhuys W, Mbimba T, Bui T, Harrison K, Sutariya V. Braintargeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target. 2011;19(9):837-845.
30. Kamel S, Ali N, Jahangir K, Shah SM, El-Gendy AA. Pharmaceutical significance of cellulose: a review. Express Polym Lett. 2008;2(11): 758-778.
31. Tien D, Schnaare RL, Kang FR, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. Aids Res Hum Retroviruses. 2005;21(10):845-853.
32. Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011;36(7):887-913.
33. Woodrow KA, CuY, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater. 2009;8(6):526-533.
34. Mahalingam A, Simmons AP, Ugaonkar SR, et al. Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother. 2011;55(4):1650-1660.
35. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol. 2008;8(6):447-457.
36. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. Plos One. 2010;5(2):e9310.
37. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-1174.Erratum in:Science. 2011;333(6042):524
38. Merrill DP, Manion DJ, Chou TC, Hirsch MS. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro. J Infect Dis. 1997;176(1):265-268.
39. Mallipeddi R, Rohan LC. Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv. 2010;7(1):37-48.
40. Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, Dash A. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis. 2009;9:198.
41. Shah LK, Amiji MM. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res. 2006;23(11):2638-2645.
42. Nowacek AS, Balkundi S, McMillan J, et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release. 2011;150(2):204-211.
43. Zhang T, Sturgis TF, Youan BBC. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm. 2011;79(3):526-536.
44. das Neves J, Michiels J, Arien KK, et al. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm Res. 2012;29(6): 1468-1484.
45. Yang J, Lee CH, Park J, et al. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J Mater Chem. 2007;17(26):2695-2699.
46. Yang LL, Mao H, Wang YA, et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small. 2009;5(2):235-243.
47. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
48. Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials. 2005;26(29):5898-5906.
49. Endsley AN, Ho RJ. Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles. J Acquir Immune Defic Syndr. 2012;61(4):417-424.
50. das Neves J, Amiji M, Sarmento B. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe? Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(4):389-399.
51. Musumeci T, Ventura CA, Giannone I, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006;325(1-2):172-179.
52. KuoYC, Chen HH. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int J Pharm. 2009;365(1-2):206-213.
53. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of antiHIV drugs. Adv Drug Deliv Rev. 2010;62(4-5):491-502.
54. Sehgal D, Vijay IK. A method for the high-efficiency of water-soluble carbodiimide-mediated amidation. Anal Biochem. 1994;218(1):87-91.
55. Larsson PG, Platz-Christensen JJ. The vaginal pH and leucocyte/ epithelial cell ratio vary during normal menstrual cycles. Eur J Obstet Gynecol Reprod Biol. 1991;38(1):39-41.
56. Mumper RJ, Bell MA, Worthen DR, et al. Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action. Drug Dev Ind Pharm. 2009;35(5):515-524.
57. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5-24.
58. Owen DH, Katz DF. A vaginal fluid simulant. Contraception. 1999;59(2):91-95.
59. Ceric F, Silva D, Vigil P. Ultrastructure of the human periovulatory cervical mucus. J Electron Microsc (Tokyo). 2005;54(5):479-484.
60. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84(21):7735-7738.
61. Cordoncardo C, Obrien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86(2):695-698.
62. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem. 1989;37(2):159-164.
63. Cordoncardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990;38(9):1277-1287.
64. Flens MJ, Zaman GJR, van der Valk P, et al. Tissue distribution of the multidrug resistance protein. Am J Pathol. 1996;148(4):1237-1247.
65. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RMW, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001;59(4):806-813.
66. Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res. 1998;15(3):423-428.
67. Valentin A, Morrow M, Poirier RH, et al. Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells. Aids Res Hum Retroviruses. 2010;26(1):79-88.
68. Bining N, Miller RA. Cytokine production by subsets of CD4 memory T cells differing in P-glycoprotein expression: effects of aging. J Gerontol A Biol Sci Med Sci. 1997;52(3):B137-B145.
69. Eagling VA, Wiltshire H, Whitcombe IWA, Back DJ. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica. 2002;32(1):1-17.